Diagnosis and management strategy of lung injury related to inflammatory bowel disease

doi:10.16138/j.1673-6087.2025.02.02

Abstract

Abstract:

Inflammatory bowel disease (IBD) is a chronic and recurrent gastrointestinal inflammatory disorder, often accompanied by extraintestinal manifestations (EIM), which can seriously affect the quality of life of IBD patients and sometimes even threaten their lives. Lung injury is a rare and easily overlooked EIM of IBD. IBD combined with lung injury includes airway diseases, interstitial lung diseases, pulmonary embolism, pleural diseases, and drug-related lung injury. This article summarizes the progress in the types, clinical characteristics, and treatment of IBD combined with lung injury, aiming to provide a strategy for its diagnosis and treatment. In the future, multidisciplinary collaboration will become the main diagnosis and treatment mode of IBD combined with lung injury.

Key words: Inflammatory bowel disease, Extraintestinal manifestations, Lung injury, Multidisciplinary team collaboration

CLC Number:

R574

GE Wensong. Diagnosis and management strategy of lung injury related to inflammatory bowel disease[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(02): 107-111.

References 32

[1]	Gordon H, Burisch J, Ellul P, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease[J]. J Crohns Colitis, 2024, 18(1): 1-37.
[2]	Pemmasani G, Loftus EV, Tremaine WJ. Prevalence of pulmonary diseases in association with inflammatory bowel disease[J]. Dig Dis Sci, 2022, 67(11): 5187-5194.
[3]	Saez A, Herrero-Fernandez B, Gomez-Bris R, et al. Pathophysiology of inflammatory bowel disease: innate immunesystem[J]. Int J Mol Sci, 2023, 24(2): 1526.
[4]	Jarmakiewicz-Czaja S, Zielińska M, Sokal A, et al. Genetic and epigenetic etiology of inflammatory bowel disease: an update[J]. Genes (Basel), 2022, 13(12): 2388.
[5]	Kröner PT, Lee A, Farraye FA, et al. Respiratory tract manifestations of inflammatory bowel disease[J]. Inflamm Bowel Dis, 2021, 27(4): 563-574. doi: 10.1093/ibd/izaa112 pmid: 32448912
[6]	Camba-Gómez M, Arosa L, Gualillo O, et al. Chemokines and chemokine receptors in inflammatory bowel disease: recent findings and future perspectives[J]. Drug Discov Today, 2022, 27(4): 1167-1175.
[7]	Du BX, Fu Y, Han YX, et al. The lung-gut crosstalk in respiratory and inflammatory bowel disease[J]. Front Cell Infect Microbiol, 2023, 13: 1218565.
[8]	Rogler G, Singh A, Kavanaugh A, et al. Extraintestinal manifestations of inflammatory bowel disease:current concepts, treatment, and implications for disease management[J]. Gastroenterology, 2021, 161(4): 1118-1132.
[9]	Jacobsen HA, Karachalia Sandri A, Weinreich UM, et al. Increased risk of obstructive lung disease in inflammatory bowel disease: a population-based cohort study[J]. United European Gastroenterol J, 2024, 12(4): 477-486.
[10]	Alhalabi M, Ali Deeb S, Ali F, et al. Ulcerative colitis-associated bronchiectasis: a rare extraintestinal manifestation of inflammatory bowel disease[J]. Medicine(Baltimore), 2022, 101(34): e30202.
[11]	Ellrichmann M, Bethge J, Boesenkoetter J, et al. Subclinical pulmonary involvement in active IBD responds to biologic therapy[J]. J Crohns Colitis, 2021, 15(8): 1339-1345. doi: 10.1093/ecco-jcc/jjab024 pmid: 33544122
[12]	Massart A, Hunt DP. Pulmonary manifestations of infammatory bowel disease[J]. Am J Med, 2020, 133(1): 39-43. doi: S0002-9343(19)30584-4 pmid: 31398306
[13]	Cheng K, Faye AS. Venous thromboembolism in inflammatory bowel disease[J]. World J Gastroenterol, 2020, 26(12): 1231-1241.
[14]	Higgins PDR, Skup M, Mulani PM, et al. Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease[J]. Clin Gastroenterol Hepatol, 2015, 13(2): 316-321.
[15]	Detrez I, Thomas D, Van Steen K, et al. Successful infliximab treatment is associated with reversal of clotting abnormalities in Inflammatory bowel disease patients[J]. J Clin Gastroenterol, 2020, 54(9): 819-825. doi: 10.1097/MCG.0000000000001290 pmid: 31789759
[16]	Tanoglu A, Tekin Ö, Düzenli T, et al. A diagnostic conundrum in a newly diagnosed ulcerative colitis patient who presented with pleuropericardial effusion[J]. Ann Colorectal Res, 2019, 7(2): 1-4.
[17]	Dierkes-Globisch A, Mohr HH. Pulmonary function abnormalities in respiratory asymptomatic patients with inflammatory bowel disease[J]. Eur J Intern Med, 2002, 13(6):385. pmid: 12225784
[18]	Georgakopoulou VE, Tarantinos K, Papalexis P, et al. Role of pulmonary function testing in inflammatory bowel diseases(Review)[J]. Med Int(Lond), 2022, 2(4): 25.
[19]	Takuro S, Manabu T, Isho I, et al. Mesalazine-induced lung injury in a child; the value of bronchoscopy[J]. Pediatr Int, 2021, 63(11): 1402-1404. doi: 10.1111/ped.14640 pmid: 34390090
[20]	Pereira FM, Marques C, Boncoraglio T, et al. Mesalazine-induced hypersensitivity pneumonitis[J]. Eur J Case Rep Intern Med, 2021, 8(1): 002194.
[21]	Sablin OA, Chernousova VV, Komlev AD. Lung disease/pneumonitis in a patient with ulcerative colitis due to mesalazine[J]. Ter Arkh, 2021, 93(2): 199-203. doi: 10.26442/00403660.2021.02.200618 pmid: 36286637
[22]	Nagy F, Molnar T, Makula E, et al. A case of interstitial pneumonitis in a patient with ulcerative colitis treated with azathioprine[J]. World J Gastroenterol, 2007, 13(2):316-319.
[23]	Ananthakrishnan AN, Attila T, Otterson MF, et al. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease[J]. J Clin Gastroenterol, 2007, 41(7): 682-688. pmid: 17667053
[24]	Atzeni F, Boiardi L, Sallì S, et al. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis[J]. Expert Rev Clin Immunol, 2013, 9(7): 649-657.
[25]	Fragoulis GE, Conway R, Nikiphorou E. Methotrexate and interstitial lung disease: controversies and questions[J]. Rheumatology(Oxford), 2019, 58(11): 1900-1906.
[26]	Quah E, Amoasii C, Mudawi T, et al. Systematic literature review investigating whether methotrexate causes chronic pulmonary fibrosis[J]. Future Healthc J, 2019, 6 Suppl 2: 4.
[27]	Aqsa A, Sharma D, Chalhoub M. Adalimumab induced interstitial lung disease[J]. Respir Med Case Rep, 2020, 29: 101012.
[28]	Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases[J]. Semin Arthritis Rheum, 2011, 41(2): 256-264.
[29]	Pugliese D, Privitera G, Schepis T, et al. Drug-related pneumonitis in patients receiving vedolizumab therapy for inflammatory bowel disease[J]. Clin Gastroenterol Hepatol, 2022, 20(6): e1483-e1487.
[30]	Brinker A, Cheng C, Chan V. Association of noninfectious pneumonia with ustekinumab use[J]. JAMA Dermatol, 2019, 155(2): 221-224. doi: 10.1001/jamadermatol.2018.4118 pmid: 30540343
[31]	Kalra SS, Chizinga M, Trillo-Alvarez C, et al. Ustekinumab associated chronic eosinophilic pneumonia[J]. J Asthma, 2021, 58(12): 1670-1674.
[32]	Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis[J]. N Engl J Med, 2022, 386(4): 316-326.